Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation

Liver Transplantation

Volumn 15, Issue 10, 2009, Pages 1336-1342

  Teicher, Elina ^a,b,c   Abbara, Chadi ^a   Duclos Vallée, Jean Charles ^a,b,c   Antonini, Teresa ^a   Bonhomme Faivre, Laurence ^a   Desbois, Delphine ^a   Samuel, Didier ^a,b,c   Vittecoq, Daniel ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CYCLOSPORIN A; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; VIRUS LOAD;

EID: 70350534041     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21818     Document Type: Article

References (33)

1. Samuel D, Weber R, Stock P, Duclos-Vallee JC, Terrault N. Are HIV-infected patients candidates for liver transplantation? J Hepatol 2008;48:697-707.
2. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003;76:370-375. (Pubitemid 36928001)
3. Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006;12:801-807.
4. Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque- Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008;47:407-417. (Pubitemid 351280708)
5. Duclos-Vallee JC, Vittecoq D, Teicher E, Feray C, Roque- Afonso AM, Lombes A, et al. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol 2005;42:341-349. (Pubitemid 40254248)
6. de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006;6:2983-2993. (Pubitemid 44777929)
7. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008. Available at: http://www.aidsinfo.nih.gov/contentfiles/ adultandadolescentgl.pdf. Accessed April 2009.
9. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007;59:342-346. (Pubitemid 47073440)
10. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-189. (Pubitemid 34032559)
11. Martin-Carbonero L, Nuñez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003;4:115-120. (Pubitemid 36410915)
12. Martinez E, Blanco J, Arnaiz J, Perez-Cuevas J, Mocroft A, Cruceta A. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268. (Pubitemid 32592358)
13. Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004;18:775-779. (Pubitemid 38535005)
14. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002;7:165-174. (Pubitemid 36427141)
15. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004;38(suppl 2):S90-S97.
16. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-134.
17. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999;62:25-31. (Pubitemid 29486478)
18. Cummins CL, Salphati L, Reid MJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 2003;305:306-314.
19. King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 2004;43:291-310. (Pubitemid 38534753)
20. Jain AB, Venkataramanan R, Eghtesad B, Marcos A, Ragni M, Shapiro R, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003;9:954-960. (Pubitemid 37098844)
21. Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007;46:941-952. (Pubitemid 47548643)
22. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007;7:2816-2820. (Pubitemid 350045781)
23. Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Turler A, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004;10:939-944. (Pubitemid 38979268)
24. Frassetto L, Baluom M, Jacobsen W, Christians U, Roland ME, Stock PG, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005;80:13-17. (Pubitemid 40980889)
25. Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther 2005;10:469-477. (Pubitemid 41059193)
26. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004;66:532-541. (Pubitemid 38981993)
27. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195. (Pubitemid 36618129)
28. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-412. (Pubitemid 41669173)
29. Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 2004;24:198-211. (Pubitemid 38209440)
30. Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005;7:139-147. (Pubitemid 41671913)
31. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
32. Da Silva B, King M, Cernohous P. Lopinavir/ritonavir safety, tolerability and efficacy in hepatitis C and/or hepatitis B infected patients: review of clinical trials. Paper presented at: 15th International AIDS Conference; 2004; Bangkok, Thailand.
33. Chihrin S, Antoniou T, Raboud J, Shen S, Govan V. Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy. AIDS Patient Care STDS 2007;21:469-478. (Pubitemid 47221642)